A meta-analysis conducted by Lu et al. in 2019 demonstrated that multiple HMG-CoA reductase inhibitors (statins) decreased the risk of all-cause mortality, cardiovascular disease-related mortality, and mortality due to respiratory failure in patients suffering from COPD patients, with the relative risk (RR) (95% CI) of 0.72 (0.63, 0.84), 0.72 (0.53, 0.98), and 0.84 (0.79, 0.89), respectively, and definitively showed that reduced CRP levels significantly [23]. The gene discussed is HMGCR; the disease is respiratory failure.